Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steven D. Harr
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 142
- Beta
- 2.19
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -6.35
Financials
Net Income
$-63.63MEBITDA
$-61.40MFree Cash Flow
$-34.41MEPS (diluted)
$-0.22Shares Outstanding (diluted)
295.67M+86.2%Operating Expenses
$65.42MCash & Debt
$160.49MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-244.17M | $-0.96 |
| 2024 | $0.00 | $-266.76M | $-1.16 |
| 2023 | $0.00 | $-283.25M | $-1.46 |
| 2022 | $0.00 | $-269.48M | $-1.43 |
| 2021 | $0.00 | $-355.93M | $-2.14 |
| 2020 | $0.00 | $-285.31M | $-1.63 |
| 2019 | $0.00 | $-130.78M | $-0.70 |
| 2018 | $0.00 | $-13.25M | $-0.07 |
Valuation
SANAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·12d ago·Neutral
Sana Biotechnology: A Shot At Diabetes Sana Biotechnology trades at a steep discount despite promising T1D assets UP421 and SC451. UP421 demonstrated durable insulin production without immunosuppression in early data, positioning SANA as a potential T1D disruptor. Cash runway is limited to 5 quarters at the current burn, making Sana dependent on the near-term success of their pipeline.
View source ↗ - Newsseekingalpha.com·40d ago·Positive
Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·45d ago·Positive
Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsseekingalpha.com·45d ago·Positive
Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·54d ago·Negative
Sana Biotechnology to Present at September 2026 Investor Conferences SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update.
View source ↗
Earnings
Thu, Nov 5(in 10 days)
Consensus estimate $-0.15 per share
Typical surprise +6.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.22 vs $-0.15miss
- Mon, May 11$-0.14 vs $-0.15beat
- Tue, Mar 3$-0.16 vs $-0.13miss
- Thu, Nov 6$-0.15 vs $-0.18beat
- Mon, Aug 11$-0.39 vs $-0.20miss
- Thu, May 8$-0.20 vs $-0.22beat
Estimates and results for SANA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SANA officers and directors.
- Bought
- —
- Sold
- $1.9m
0 trades
4 trades
- Fmr Llcsold
- Fmr Llcsold
- Fmr Llcsold
- Fmr Llcsold
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SANA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.